Illegal Possession of Drugs: Polish Man Faces 10-Year Sentence

Regulations by 2FIRSTS.ai
Nov.28.2023
Illegal Possession of Drugs: Polish Man Faces 10-Year Sentence
A housing in Lublin, Poland drew police attention due to excessive noise, leading to the discovery of drugs and illegal e-cigarettes.

In recent days, a housing property in Lublin, Poland, attracted police attention due to excessive nighttime noise. During the investigation, the police discovered a quantity of drugs and illegal e-cigarettes, leading to the detention of all individuals present at the scene.

 

After conducting a further search of the 24-year-old man's room, the authorities have discovered 850 grams of ephedrine and 200 e-cigarettes without the required Polish tax stamps.

 

Currently, a 24-year-old man has been charged with the illegal possession of a large quantity of drugs. According to the court's decision, he will be temporarily detained for three months and could potentially face a maximum sentence of 10 years imprisonment.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris Japan adds “Electric Purple” to IQOS ILUMA i range, expands to convenience stores from Feb. 3
Philip Morris Japan adds “Electric Purple” to IQOS ILUMA i range, expands to convenience stores from Feb. 3
Philip Morris Japan (PMJ) said on Jan. 29 it has introduced “Electric Purple” as a new standard color option for its IQOS ILUMA i heated tobacco device lineup, covering three models with prices unchanged. The new color will be available from Jan. 29 via the company’s official online and store channels, with sales expanding to convenience stores and some tobacco retailers from Feb. 3.
Jan.29 by 2FIRSTS.ai
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
Report says illegal vapes “threaten UK high streets” as 55% of councils seized thousands last year
Report says illegal vapes “threaten UK high streets” as 55% of councils seized thousands last year
The latest annual Illegal Vapes and Nicotine Product Report says nearly 5 million illegal vapes have been seized over the last three years—equivalent to three seized every minute—with a street value of £39m (USD equivalent not provided in the source; exchange-rate basis not stated). It says 1.3 million were seized last year and that 55% of UK council areas seized thousands of illegal products over the year.
Feb.26 by 2FIRSTS.ai
JTI reshuffles regional leadership; Gabriella Offeddu to lead Romania, Moldova and Bulgaria
JTI reshuffles regional leadership; Gabriella Offeddu to lead Romania, Moldova and Bulgaria
Japan Tobacco International (JTI) has appointed Gabriella Offeddu as general manager for Romania, Moldova and Bulgaria, effective January 2026.
Jan.22 by 2FIRSTS.ai
Iowa Targets Smoking Products With Tax Plan: Cigarettes to National Average, 15% Tax on Vapes and Consumable Hemp
Iowa Targets Smoking Products With Tax Plan: Cigarettes to National Average, 15% Tax on Vapes and Consumable Hemp
Iowa Gov. Kim Reynolds is proposing higher taxes on cigarettes and new taxes on vaping and consumable hemp products, arguing tobacco use is a key driver of lung cancer. The proposal comes as University of Iowa researchers release preliminary findings suggesting Iowa’s late-stage lung cancer burden is higher—and improving more slowly—than in neighboring states.
Feb.06 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11